Salute e Benessere

DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for…

DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the semester ended June 30, 2025, of its Half-Year Report with the French market...
Nasdaq GlobeNewswire
29/07/2025

DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results

DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today reported financial results for the Second Quarter of 2025. The quarterly and half-year financial statements were approved by the Board of Directors on July 29, 2025. Financial Highlights for the Second Quarter Ended June 30, 2025The Company’s interim condensed...
Nasdaq GlobeNewswire
29/07/2025

Inventiva Reports Preliminary 2025 First-Half Financial Information¹

Cash and cash equivalents at €122.1 million and €24.6 million in short-term deposits 2as of June 30, 2025Revenues of €4.5 million recorded in H1 2025Daix (France), New York City (New York, United States), July 29, 2025– Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported...
Nasdaq GlobeNewswire
29/07/2025

Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments

Globally, the cancer‑drug sector is projected to surpass US$900billion in sales by 2034, according to Vision Research Reports. Next‑generation therapeutics (those powered by precision and personalized medicine) are pegged by Precedence Research to hit US$175.2billion during that same time period, growing at a 7.35% CAGR. Globally, the cancer‑drug sector is projected to surpass US$900billion in sales by 2034, according to Vision Research Reports. Next‑generation therapeutics (those powered...
PR Newswire
29/07/2025

AI Just Got a Green Light from the White House--Here's What That Means for…

According to Accenture, AI could inject an additional $461 billion into the healthcare sector by 2035, as it surpasses the $2.26 trillion mark. Now, as AI makes its move into the healthcare space, experts are working to help guide these new solutions towards being more accurate, in a space where AI's inaccuracies (known as "hallucinations") are not an option. Thankfully, there are several players making important advancements in diagnostics, drug development, and workflow, through the…
PR Newswire
29/07/2025

FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: ALZHEIMER'S…

The CPG provides clear evidence-based, brand-agnostic recommendations to support more accurate and accessible diagnosis of Alzheimer's using blood-based biomarker tests. The recommendations are linked to a systematic review using a robust and transparent methodology, and will be updated regularly as evidence evolves. The CPG provides clear evidence-based, brand-agnostic recommendations to support more accurate and accessible diagnosis of Alzheimer's using blood-based biomarker tests. The...
PR Newswire
29/07/2025

First-half 2025 results

Press Release Paris, 29th July 2025 7% to 9% 2025 Core EBITDA margin guidance reaffirmed, with ambition to be in the upper part of the range, supported by thorough execution of the FOCUS-27 plan, and despite more challenging topline€412.1 million Net Sales (- 8.2% year-on-year)Challenging year-on-year comparison, primarily due to a €21 million one off in H1 2024, excluding this exceptional impact, sales would have declined by 4%EBITDA at €5.0 million compared to €(1.4) million...
Nasdaq GlobeNewswire
29/07/2025

Hansa Biopharma announces key executive appointments to support continued growth

Sandra Frithiof brings over 25 years of experience in human resources in different industries, to Hansa. Most recently, Sandra was HR Director at Ayvens Sweden AB, a global leader in the mobility sector. Prior to Ayvens, Sandra was VP Human Resources at Calliditas Therapeutics, where she built the Global HR organization to support the company's entry into the US market. Previously, Sandra was Head of HR and COO at Ramberg Advokater, a Swedish law firm and earlier in her career, Sandra held HR…
PR Newswire
29/07/2025

EssilorLuxottica: Publication of the 2025 Interim Financial Report

Publication of the 2025 Interim Financial ReportParis, France(29 July 2025 – 6:30 pm)– The Board of Directors of EssilorLuxottica met on July 28, 2025 to approve the condensed consolidated interim financial statements for the six-month period ended June 30, 2025.EssilorLuxottica’s 2025 Interim Financial Report has been published today. The Interim Financial Report comprises the First-half 2025 Management Report, the Condensed Consolidated Interim Financial Statements, the Statutory...
Nasdaq GlobeNewswire
29/07/2025

RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES IN THE FIRST HALF OF 2025…

Consolidated net revenue of € 1,323.8 million in the first half of 2025, +11.7% or +7.8% on a like-for-like basis (3)and at constant exchange rates (CER)EBITDA (1)of € 496.3 million, +9.6%, margin on revenue of 37.5% Adjusted net income (2)of € 327.8 million, +8.9% Net income of € 216.1 million, -4.1%Free cash flow (4)of € 256.8 million, +€ 0.2millionvs first half of 2024Net debt (5)at € 2,127.1 million, just...
Nasdaq GlobeNewswire
29/07/2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2025

Aggregated presentation by day and by marketStatement of transactions in own shares from July 21st to July 25th 2025 Name of the issuerIdentity code of the issuer(Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1121/07/2025FR0010259150 350 ...
Nasdaq GlobeNewswire
29/07/2025

AI in Telehealth & Telemedicine Market worth $27.14 Billion by 2030 with 36.4%…

Browse in-depth TOC on "AI in Telehealth & Telemedicine Market" Browse in-depth TOC on "AI in Telehealth & Telemedicine Market" 409 - Tables 58 - Figures 380 - Pages By application,the primary care segment commanded the most significant proportion of the AI in telemedicine market due to an increased need for day-to-day healthcare, such as check-ups, chronic condition management, and preventive care, well-suited for AI implementation. These platforms leverage AI to...
PR Newswire
29/07/2025

Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR |…

Download Sample Pages of the Report: https://www.skyquestt.com/sample-request/cell-therapy-market Download Sample Pages of the Report:https://www.skyquestt.com/sample-request/cell-therapy-market Cell Therapy Market Dynamics Surge in incidence of chronic and genetic diseases, including cancer, cardiovascular disorders, and autoimmune conditions is primarily boosting the demand for cell therapies. These therapies offer promising curative potential, especially for patients...
PR Newswire
29/07/2025

Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE)…

"Understanding aging and dementia requires both advanced technology and deeply characterized cohorts," said Prof. Monique Breteler, Director of Population Health Sciences at DZNE and Principal Investigator of the Rhineland Study. "Integrating Alamar's multiplex panels into our research opens new opportunities to decode the molecular signatures of brain aging." "Understanding aging and dementia requires both advanced technology and deeply characterized cohorts," said…
PR Newswire
29/07/2025

Kyowa Kirin Announces Abstract Presentation at the European Academy of…

Title: Efficacy & Safety of OX-40 Receptor Targeting with Rocatinlimab in Moderate-to-Severe Atopic Dermatitis: Results from the Phase 3 ROCKET-IGNITE Trial Title: Efficacy & Safety of OX-40 Receptor Targeting with Rocatinlimab in Moderate-to-Severe Atopic Dermatitis: Results from the Phase 3 ROCKET-IGNITE Trial Presenter: Emma Guttman-Yassky, MD, PhD Date: Friday, September 19 thTime: 4:40 –4:50 pm CESTSession: FC 08 Atopic Dermatitis Location: Paris Convention Centre, Pavillon 7...
PR Newswire
29/07/2025

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform &…

Presentation to highlight the Company’s proprietary protein-misfolding platform, EpiSelect TM, used to develop PMN310Posters highlighting PRECISE-AD, the Company’s Phase 1b clinical trial design and optimization of biomarkers in ADProgress with trial enrollment following DSMB recommendation to proceed to second dose level CAMBRIDGE, Massachusetts, July29, 2025(GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to...
Nasdaq GlobeNewswire
29/07/2025

ClariMed Inc. Achieves ISO 13485:2016 Certification, Strengthening Global…

This certification represents a transformative milestone that expands ClariMed's capabilities to serve the evolving needs of the global MedTech and pharmaceutical industries. As regulatory requirements continue to evolve globally, this certification empowers ClariMed to deliver an expanded portfolio of services—from human factors research and usability studies to strategic advisory, quality management, and digital solutions—all unified by rigorous quality standards that accelerate clients' path…
PR Newswire
29/07/2025

Maziar Mike Doustdar appointed as president and chief executive officer of Novo…

Bagsværd, Denmark, 29 July 2025 – Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective 7 August 2025. Mike Doustdar succeeds Lars Fruergaard Jørgensen, who will step down as president and chief executive officer on the same date. The company also announced other executive-level changes, effective 7 August.Mike Doustdar, currently Novo Nordisk’s executive vice president of International Operations, has a strong track...
Nasdaq GlobeNewswire
29/07/2025

ARTBIO Announces $132 Million Series B Financing to Advance Pipeline of Alpha…

Funding will support the advancement of lead asset AB001 through Phase II development, the progress of additional undisclosed programs toward IND readiness, and the expansion of a unique supply chain leveraging ARTBIO's proprietary generator technology. Funding will support the advancement of lead asset AB001 through Phase II development, the progress of additional undisclosed programs toward IND readiness, and the expansion of a unique supply chain leveraging ARTBIO's proprietary generator…
PR Newswire
29/07/2025

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent…

~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026;~ Company expects to present AMT-130 topline three-year data in September 2025 ~~ Presented case study from first participant treated with AMT-260 for refractory mesial temporal lobe epilepsy showing 92% seizure reduction with no serious adverse events through first five months of follow up ~ ~ Appointment of Kylie O’Keefe...
Nasdaq GlobeNewswire
29/07/2025

Novo Nordisk lowers sales and operating profit outlook for 2025

Bagsværd, Denmark, 29 July 2025 – Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for the first six months of 2025 and updated full-year sales and operating profit outlook at CER.In the first six months of 2025, Novo Nordisk’s sales increased by 18% and operating profit increased by 29%, both at CER. Sales growth in the first six months of 2025 was positively impacted by gross-to-net sales adjustments related to prior years, including an...
Nasdaq GlobeNewswire
29/07/2025

Alkermes plc Reports Second Quarter 2025 Financial Results

— Company Reiterates 2025 Financial Expectations — — Company Reiterates 2025 Financial Expectations — — Alkermes to Present Detailed Vibrance-1 Results at Upcoming World Sleep Congress — DUBLIN , July 29, 2025 /PRNewswire/ --Alkermes plc(Nasdaq: ALKS) today reported financial results for the second quarter of 2025. "Our second quarter results reflect strong performance across all three of our proprietary products and robust profitability and cash flow...
PR Newswire
29/07/2025

Leo Cancer Care Receives FDA 510(k) Clearance for Marie® - A Revolutionary…

"This clearance marks a major milestone not just forLeo Cancer Care, but for the future of cancer treatment," saidStephen Towe, CEO ofLeo Cancer Care. "We've long believed there's a better, more human way to deliver radiotherapy. One that puts the patient at the heart of the treatment experience and embraces smarter, more compassionate design. Marie is the embodiment of that belief." Particle therapies such as proton and carbon ion therapy have long been considered the…
PR Newswire
29/07/2025

Bentley Home embraces Marbella with eight exclusive residences in partnership…

The development has entered its private sales phase with an exceptional reception: over 50% of the units have already been reserved ahead of public commercialization. The development has entered its private sales phase with an exceptional reception: over 50% of the units have already been reserved ahead of public commercialization. The eight residences, with prices starting at 3,450,000€ and ranging between 350 and 480 m², include 3 to 4 bedrooms, private terraces, pools, exclusive access,...
PR Newswire
29/07/2025
Altri  Comunicati